

Supplementary Table 2. Comparative Analysis Results of Variables among Risk Groups

Variables	Low risk group (n=550)	Intermediate risk group (n=429)	High risk group (n=1433)	p value
Clinical parameters				
Age, yr, median (IQR)	64.0 (54.9–71.0)	66.2 (57.1–72.0)	67.1 (58.5–73.2)	<0.001
<65, n (%)	297 (54.0)	192 (44.8)	610 (42.6)	<0.001
≥65, n (%)	253 (46.0)	237 (55.2)	823 (57.4)	
Gender, n (%)				0.749
Male	417 (84.1)	335 (84.2)	1095 (82.9)	
Female	79 (15.9)	63 (15.8)	226 (17.1)	
Preoperative urine cytology, n (%)				<0.001
Negative	335 (70.1)	267 (70.3)	530 (40.3)	
Atypical cells	92 (19.2)	67 (17.6)	290 (22.1)	
Positive for malignant cells	51 (10.7)	46 (12.1)	495 (37.6)	
Tumor morphology, n (%)				<0.001
Papillary	517 (94.0)	370 (86.2)	1173 (82.2)	
Non-papillary (sessile/flat/mixed)	33 (6.0)	59 (13.8)	254 (17.8)	
Pathological parameters				
Muscle layer included, n (%)				<0.001
Absent	419 (76.5)	278 (65.0)	783 (54.7)	
Present	129 (23.5)	150 (35.0)	649 (45.3)	
Postoperative parameters				
Immediate intravesical chemotherapy, n (%)				0.029
No	465 (84.5)	354 (82.5)	1139 (79.5)	
Yes	85 (15.5)	75 (17.5)	293 (20.5)	
Additional intravesical chemotherapy, n (%)				0.021
No	474 (86.3)	343 (80.0)	1170 (82.0)	
Yes	75 (13.7)	86 (20.0)	256 (18.0)	
BCG induction, n (%)				<0.001
No	416 (75.6)	237 (55.2)	460 (32.1)	
Yes	134 (24.4)	192 (44.8)	973 (67.9)	
BCG maintenance, n (%)				<0.001
No	417 (82.9)	263 (72.1)	893 (66.0)	
Yes (SWOG or monthly)	86 (17.1)	102 (27.9)	460 (34.0)	
Overall follow-up duration (months), median (IQR)	38.5 (25–54)	37 (25–52.5)	36 (25–51)	0.893
Median first time to recurrence (months)	11 (6–20)	10 (5–20)	9 (4–19)	0.517
Recurrence, n (%)				<0.001
No	403 (73.3)	291 (67.8)	849 (59.4)	
Yes	147 (26.7)	138 (32.2)	581 (40.6)	
Progression, n (%)				<0.001
No	532 (97.4)	413 (96.7)	1318 (92.4)	
Yes	14 (2.6)	14 (3.3)	109 (7.6)	
Muscle invasion	8	11	60	
Distant metastasis	6	3	49	

IQR, interquartile range; BCG, Bacillus Calmette-Guérin; SWOG, Southwest Oncology Group.